Pantoprazole sodium

This page contains recent news articles, when available, and an overview of Pantoprazole sodium but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Pantoprazole sodium (when available)

Pharmacology and use:
Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. Short-term (up to 16 weeks) treatment of erosive esophagitis.

Mechanism Of Action:
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H⁺,K⁺ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

News Articles on Pantoprazole

복지부, '항파킨슨제제' 건강보험급여 대�? 추가  -  ‎Aug 27, 2009‎
...프로톤 펌프 억제 주사제�?� Omeprazole sodium(로섹주 등), Pantoprazole sodium(�?토�?주 등)�?� 소화성 궤양으로 �?�한 위장관 출혈환�? 중 활�?�성 출혈 �?는 재 헬스코리아뉴스

간염약 내성치료�? 헵세�?�·바�?��?�루드 급여  -  ‎Aug 27, 2009‎
...프로톤 펌프 억제 주사제 omeprazole sodium(로섹주 등), pantoprazole sodium(�?토�?주 등) 등�?� 소화성 궤양으로 �?�한 위장관 출혈환�? 중 활�?�성 출혈 �?는 재출혈 데일리팜

레보비르 내성치료 '바�?��?�루드1mg' 급여  -  ‎Aug 10, 2009‎
...소화성 궤양용제�?� 프로톤 펌프 억제 주사제 omeprazole sodium(로섹주 등), pantoprazole sodium(�?토�?주 등) 등�?� 고위험군�? 급여가 확대�??다. 데일리팜

Pharmaceutical industry: Duty slashed to 5% on import of raw ...  -  ‎Jun 23, 2009‎
...customs duty has been reduced on import of aflacalcidole, flurbiprofen, aspirin, amlodipine, loratadine, pantoprazole sodium, deferirone, lamivudine, Daily Times

Acute allergic interstitial nephritis after use of pantoprazole  -  ‎Mar 4, 2009‎
4 , 6 In the 2008 Canadian drug monograph for pantoprazole sodium, interstitial nephritis was listed as a reported adverse event in postmarketing use for CMAJ

MoH suspends use, sales of Yixin Pharma injection  -  ‎Mar 8, 2009‎
INTERFAX-CHINA - The Ministry of Health (MoH) has suspended the use and sales of pantoprazole sodium injections manufactured by Jilin Yixin Pharmaceutical Interfax China

Canada: Canada: The IP Year 2008 In Review: Patents (Part 1 of 3)  -  Dec 23, 2008
Inc. and Altana Pharma AG ("Solvay") sought an order prohibiting the issuance of a NOC for Apotex's enteric coated tablets of pantoprazole sodium. Mondaq News Alerts (registration),

China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials  -  Sep 10, 2008
Doxofylline injection is for the treatment of asthma; -- Pantoprazole sodium injection is for the treatment of canker sores; -- Calcium Folinate Earthtimes (press release),

US Attorney Subpoenas Protonix Marketing and Pricing Documents  -  Aug 6, 2008
...for Protonix (pantoprazole sodium), as well as pricing practices for both the IV and tablet formulations of the drug, according to SEC filings. FDA news (subscription),

Wyeth Reports Earnings Results for the 2008 Second Quarter and ...  -  Jul 23, 2008
Sales of PROTONIX(R) (pantoprazole sodium), Wyeth's branded proton pump inhibitor indicated for gastroesophageal reflux disease, continued to be adversely FOXBusiness

Wyeth, Nycomed Take Teva to Court Over Heartburn Drug  -  Jun 25, 2008
Teva notified Nycomed and Wyeth in a letter dated April 25 that it had filed an ANDA for injectable Protonix (pantoprazole sodium) that included a Paragraph FDA news (subscription),

Positive Clinical Data with Santarus' ZEGERID Capsules in ...  -  May 24, 2008
The clinical study evaluated the effect of morning dosing of immediate-release ZEGERID Capsules, Protonix (pantoprazole sodium) Delayed-Release Tablets 40 Stockhouse,

Positive Clinical Data with Santarus' ZEGERID Capsules in ...  -  May 19, 2008
The clinical study evaluated the effect of morning dosing of immediate-release ZEGERID Capsules, Protonix(R) (pantoprazole sodium) Delayed-Release Tablets PR-Inside.com (Pressemitteilung),

Santarus' study reveals ZEGERID produces notably greater and ...  -  May 19, 2008
ZEGERID capsules were compared with 40 mg of Protonix or pantoprazole sodium delayed-release tablets, and 30 mg of Prevacid or lansoprazole delayed-release RTT News,

Santarus Reports First Quarter 2008 Financial Results  -  May 7, 2008
...two other marketed PPIs, Prevacid ® (lansoprazole) delayed release capsules 30 mg and Protonix ® (pantoprazole sodium) delayed-release tablets 40 mg. Earthtimes (press release),

Wyeth Reports Earnings Results for the 2008 First Quarter  -  Apr 22, 2008
Sales in the 2008 first quarter of PROTONIX(R) (pantoprazole sodium), Wyeth's branded proton pump inhibitor indicated for gastroesophageal reflux disease, MSN Money

Sun Pharma launches generic protonix tablets  -  Feb 21, 2008
Sun Pharmaceutical announced that it has commercially launched generic pantoprazole sodium delayed release (DR) tablets, 40 mg, which is AB-rated to Wyeth's Express Pharma,

Santarus Reports Fourth Quarter and Full Year 2007 Financial Results  -  Mar 3, 2008
...mg and two leading PPIs, Protonix ® (pantoprazole sodium) delayed-release tablets 40 mg and Prevacid ® (lansoprazole) delayed-release capsules 30 mg. Business Wire (press release),

Santarus Q4 2007 Earnings Call Transcript  -  Mar 3, 2008
...or pantoprazole sodium was launched, followed in late January of this year by an authorized generic and a third generic pantoprazole sodium entry. Seeking Alpha,

Brand Names/Synonyms:
Pantoprazole sodium is also known by the following brand names and/or synonyms:
BY 1023; CHEMBANK1787; Pantoloc; Pantoprazol [Inn-Spanish]; Pantoprazole; Pantoprazole Na; Pantoprazole Sodium; Pantoprazole [Usan:Ban:Inn]; Pantoprazolum [Inn-Latin]; Pantoprozole; Protonix; Protonix I.V.; Protonix Iv

Drug Category:
Pantoprazole sodium is categorized under the following by the FDA: Anti-ulcer Agents; Proton-pump Inhibitors; ATC:A02BC02

Dosage Forms:
TABLET (ENTERIC-COATED)

Absorption:
Pantoprazole is well absorbed; it undergoes little first- pass metabolism resulting in an absolute bioavailability of approximately 77%.

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-3H-benzoimidazole

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.